ReviewFrontiers in allergy2025
Gut microbiota-metabolome crosstalk in allergic diseases: mechanistic insights and translational opportunities.
Review in Frontiers in allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Gut microbiota-immune-metabolic crosstalk in acute lung injury: integrating the gut-lung axis from mechanism to therapeutic targeting.Seminars in immunopathology · 2026Review
- Gut Microbiome Alterations by Allergen Sensitisation and Symptom Severity in Paediatric Allergic Rhinitis.Allergy · 2026Article
- Type 2 Inflammatory Diseases: The Crossroads of Immunity and Metabolism.Research (Washington, D.C.) · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiota and its metabolites play important roles in the pathogenesis of various diseases. The diversity of the gut microbiota is closely related to the development and function of the human immune system. Dysbiosis, characterized by alterations in the species, quantity, and distribution of microbial community, may disrupt immune tolerance mechanisms, thereby inducing excessive immune responses to allergens and increasing the risk of allergic diseases. Various metabolites, such as short-chain fatty acids (SCFAs), bile acids, and amino acid metabolites, exert significant regulatory effects on the development of allergic diseases by modulating immune cell function, maintaining intestinal barrier integrity, and participating in signal transduction pathways. A comprehensive investigation into the relationship between allergic diseases and gut microbiota and their metabolites not only aids in elucidating the pathogenesis of allergic diseases but also provides novel insights and a theoretical foundation for developing innovative diagnostic methods, preventive strategies, and therapeutic options. This article systematically reviews the latest findings regarding the mutual influence between gut microbiota and the metabolome in host immune regulation, as well as the impact of this interaction on the development of allergic diseases, aiming to offering new strategies for the prevention and treatment of allergic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.